Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

First Affiliated Hospital of Zhejiang University: Clinical Trials & FDA Approval Profile

First Affiliated Hospital of Zhejiang University (Global / Institutional) sponsors 73 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 46 active protocols (33 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.4%
Median Closed Enrollment vs National (145 pts)65 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for First Affiliated Hospital of Zhejiang University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)73
Active Pipeline (Recruiting Now)46 (33)
Completed vs Stopped Early2 / 1 (1.4%)
Median Closed Actual Enrollment65 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With First Affiliated Hospital of Zhejiang University
Hospital Research SiteLocationShared Protocols
The First Affiliated Hospital, Zhejiang University School of MedicineHangzhou, Zhejiang28
The First Affiliated Hospital of Anhui Medical UniversityHefei, Anhui5
Zhongshan Hospital Fudan UniversityShanghai4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by First Affiliated Hospital of Zhejiang University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07396480Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem CelPhase IIIRECRUITING
NCT07707687Safety and Efficacy of Eculizumab in High-risk TA-TMAPhase IIRECRUITING
NCT07692841Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic DonorsPhase IIIRECRUITING
NCT06611813Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)Phase IIRECRUITING
NCT06977893Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-Phase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the First Affiliated Hospital of Zhejiang University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI